王浩楠;梁士兵;姚晓玲;来保勇;文天元;苏宁;
WANG Hao-nan;LIANG Shi-bing;YAO Xiao-ling;LAI Bao-yong;WEN Tian-yuan;SU Ning;School of Basic Medicine, Guangzhou University of Chinese Medicine;School of Basic Medicine, Shanxi University of Chinese Medicine;Center of Evidence-based Medicine, Beijing University of Chinese Medicine;the Third Affiliated Hospital, Beijing University of Chinese Medicine;the First Clinical Medical College, Shandong University of Traditional Chinese Medicine;

• 1:广州中医药大学基础医学院
• 2:山西中医药大学基础医学院
• 3:北京中医药大学循证医学中心
• 4:北京中医药大学第三附属医院

摘要(Abstract)：

为系统评价复方甘草酸苷注射液(Compound Glycyrrhizin Injection,CGI)改善慢性乙型肝炎(chronic hepatitis B,CHB)肝损伤的有效性和安全性。该研究系统检索了PubMed、Web of Science、CBM、CNKI、Wanfang和VIP数据库,检索时限为建库至2020年2月10日。纳入CGI治疗CHB的随机对照试验(randomized controlled trial,RCT),由2名作者独立对纳入研究进行资料提取,并采用Cochrane偏倚风险评价工具对纳入研究进行方法学质量评价。应用RevMan 5.3软件进行数据统计分析。最终纳入18项双臂RCT,1 915例受试者。所有纳入研究的方法学质量总体不高。对于CGI vs甘草酸二铵,CGI在提高临床总有效率上优于对照组,而在提高ALT复常率、降低ALT及AST水平上2组无统计学差异;对于CGI vs甘草酸二铵+其他一般保肝药,CGI在降低AST水平上优于对照组,而在降低ALT水平和提高临床总有效率上2组无统计学差异;对于CGI+其他常用药(包括能量合剂、谷胱甘肽、维生素及门冬氨酸钾镁等)vs甘草酸二铵+其他常用药,CGI联合其他常用药在降低ALT及AST水平、提高临床总有效率上均优于对照组,而在提高ALT复常率上2组无统计学差异;对于CGI+其他常用药vs其他常用药,CGI联合其他常用药在降低ALT及AST水平、提高临床总有效率上均优于对照组;对于CGI+维生素vs甘草酸二铵+门冬氨酸钾镁+维生素,在降低AST水平上2组无统计学差异。少数纳入研究报告了CGI单独或联合其他药物使用过程中会引起轻度不良反应。研究结果表明,CGI对改善CHB肝损伤具有一定疗效,目前证据尚不足以证明CGI会引起较严重安全性问题。未来仍需更多严格设计、足够样本量并严格实施的RCT进一步评价CGI改善CHB肝损伤的效果。
To evaluate the efficacy and safety of Compound Glycyrrhizin Injection(CGI) in improving liver damage in chronic hepatitis B(CHB). PubMed, Web of Science, SinoMed, CNKI, Wanfang and VIP databases were retrieved from their inception to February 10, 2020. The randomized controlled trial(RCT) of CGI in the treatment of CHB was included. Data were independently extracted by two authors, and the methodological quality was evaluated using the Cochrane bias risk assessment tool by other two authors. Statistical analysis was performed using RevMan 5.3 software. A total of 18 two-armed RCTs were included, involving 1 915 participants. The methodological quality of all studies included was generally low. In the comparison between CGI and diammonium glycyrrhizinate, the results showed that CGI was superior to the control group in improving the overall clinical effectiveness, but there was no statistical difference between the two groups in increasing ALT normalization rate, reducing ALT and AST level. In the comparison between CGI and diammonium glycyrrhizinate+other general hepatoprotective drugs, the results showed that CGI was superior to the control group in reducing AST level, while there was no statistical difference between the two groups in reducing ALT level and increasing overall clinical effectiveness. In the comparison between CGI+other commonly used drugs(including energy mixture, glutathione, vitamins, potassium magnesium aspartate) and diammonium glycyrrhizinate+other commonly used drugs, the results showed that CGI combined with other commonly used drugs was better than the control group in reducing ALT and AST level and improving the clinical total effective rate, and there was no statistical difference between the two groups in increasing the rate of ALT normalization. In the comparison between CGI+other commonly used drugs and other commonly used drugs, the results showed that CGI combined with other commonly used drugs was superior to the control group in reducing ALT and AST level and improving the overall clinical effectiveness. In the comparison between CGI+vitamins and diammonium glycyrrhizinate+potassium magnesium aspartate+vitamins, the results showed no statistical difference between the two groups in reducing AST level. A small number of studies included reported that CGI caused mild adverse reactions when used alone or in combination with other drugs. Based on the results, CGI has a certain effect in improving CHB liver damage, but the evidence is not enough to prove that CGI would cause serious adverse events. In the future, more well-designed and strictly-enforced RCT with an adequate sample size are needed to further evaluate the effect CGI in alleviating CHB liver damage.

关键词(KeyWords)： 复方甘草酸苷注射液;慢性乙型肝炎;肝损伤;系统评价;Meta分析
Compound Glycyrrhizin Injection;chronic hepatitis B;liver damage;systematic review;Meta-analysis

Abstract:

Keywords:

基金项目(Foundation): 广东省本科高校教学质量与教学改革工程项目(粤教高函2017214号)

作者(Author): 王浩楠;梁士兵;姚晓玲;来保勇;文天元;苏宁;
WANG Hao-nan;LIANG Shi-bing;YAO Xiao-ling;LAI Bao-yong;WEN Tian-yuan;SU Ning;School of Basic Medicine, Guangzhou University of Chinese Medicine;School of Basic Medicine, Shanxi University of Chinese Medicine;Center of Evidence-based Medicine, Beijing University of Chinese Medicine;the Third Affiliated Hospital, Beijing University of Chinese Medicine;the First Clinical Medical College, Shandong University of Traditional Chinese Medicine;

Email:

DOI: 10.19540/j.cnki.cjcmm.20200705.501

参考文献(References)：

• [1] 慢性乙型肝炎诊断标准(2015年版)[J].中西医结合肝病杂志,2015,25(6):384.
• [2] WHO.Global hepatitis report[EB/OL].[2020- 04- 05].https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
• [3] LIU J,LIANG W,JING W,et al.Countdown to 2030:eliminating hepatitis B disease,China[J].Bull World Health Organ,2019,97(3):230.
• [4] 王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2648.
• [5] YAN H,ZHONG G,XU G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife,2012,1:e00049.
• [6] 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019,35(8):1693.
• [7] SARIN S K,KUMAR M,LAU G K,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1.
• [8] TERRAULT N A,LOK A,MCMAHON B J,et al.Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J].Hepatology,2018,67(4):1560.
• [9] OFLIVER E A F.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370.
• [10] HOU J,WANG G,WANG F,et al.Guideline of prevention and treatment for chronic hepatitis B (2015 update)[J].J Clin Transl Hepatol,2017,5(4):297.
• [11] 王宇明,于乐成.肝脏炎症及其防治专家共识[J].中国实用内科杂志,2014,34(2):152.
• [12] ANDERSSON U,TRACEY K J.HMGB1 is a therapeutic target for sterile inflammation and infection[J].Annu Rev Immunol,2011,29:139.
• [13] MAHMOUD A M,AL D H.18beta-glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity:potential role of PPARgamma and Nrf2 upregulation[J].Genes Nutr,2015,10(6):41.
• [14] 甘草酸制剂肝病临床应用专家共识[J].临床肝胆病杂志,2016,32(5):844.
• [15] 一戸彰,伊藤進,五十嵐正彦,等.慢性肝疾患に対する強力ネオミノファーゲンC(SNMC)の治療知見[J].臨牀と研究,1976,53(8):2532.
• [16] International Conference on Harmonisation Expert Working Group.International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use.ICH harmonised tripartite guideline.Guideline for good clinical practice CFR & ICH Guidelines[S] Vol.1,PA19063-2043,USA:Barnett International/PAREXEL,1997.
• [17] HIGGINS J P,ALTMAN D G,GOTZSCHE P C,et al.The cochrane collaboration′s tool for assessing risk of bias in randomized trials[J].Brit Med J,2011,18(343):d5928.
• [18] 杨昊昕,苟金,黄坡,等.八宝丹胶囊治疗病毒性肝炎的疗效和安全性系统评价及Meta分析[J].中国中药杂志,2019,44(22):4953.
• [19] 李德恒,黄坡,李博,等.肝泰舒胶囊治疗病毒性乙型肝炎的系统评价与Meta分析[J].中国中药杂志,2019,44(13):2858.
• [20] 郑文江,彭紫荆,严倩,等.桑白皮汤加减治疗慢性阻塞性肺疾病急性加重期的Meta分析和试验序贯分析[J].中国中药杂志,2019,44(17):3806.
• [21] 文晓飞.复方甘草酸苷治疗慢性乙型肝炎120例疗效观察[J].中国美容医学,2011,20(z5):302.
• [22] 翟洪波,张红.复方甘草酸苷治疗慢性乙型肝炎的疗效观察[J].中国冶金工业医学杂志,2007(S1):108.
• [23] 鹿成.复方甘草酸苷治疗慢性乙型肝炎的临床可行性研究[J].中外医疗,2017,36(6):123.
• [24] 王新军,王娟.复方甘草酸苷治疗慢性乙型肝炎的临床评价[J].中国美容医学,2012,21(14):317.
• [25] 徐婕,吕晓玲,黄新造,等.复方甘草酸苷治疗慢性乙型肝炎疗效观察[J].时珍国医国药,2007,17(1):185.
• [26] 赫琰.复方甘草酸苷治疗慢性乙型肝炎临床研究[J].天津药学,2010,22(3):38.
• [27] 王丽,胡蓉,陈竹,等.复方甘草酸苷治疗慢性重型乙型肝炎的疗效观察[J].现代预防医学,2010,37(13):2557.
• [28] 侯周华,李聪智,谢玉桃,等.复方甘草酸苷治疗慢性重型乙型肝炎的临床研究[J].中国现代医学杂志,2008,18(16):2409.
• [29] 杨景毅,倪辉,冼永超,等.复方甘草酸苷治疗慢性乙型肝炎疗效分析[J].临床合理用药杂志,2009,2(15):15.
• [30] 李勇,吴洪文,唐小鹤.复方甘草酸苷治疗乙型肝炎的作用研究[J].中国现代药物应用,2008,2(9):25.
• [31] 张朝阳.复方甘草酸苷注射液用于慢性乙肝患者的疗效观察[J].临床研究,2014,22(4):77.
• [32] 张亚楠,徐瑞峰.复方甘草酸苷注射液在慢性乙型肝炎治疗中的应用效果观察[J].海峡药学,2018,30(10):214.
• [33] 杨玉贵.复方甘草酸苷注射液治疗慢性乙型肝炎临床疗效的研究[J].医药论坛杂志,2013,34(12):120.
• [34] 杨红泽.复方甘草酸苷(美能)治疗慢性乙型肝炎的疗效观察[J].传染病信息,2006,19(3):149.
• [35] 赵远怀,向际兵,罗乐平,等.50例采用复方甘草酸苷治疗慢性乙型肝炎临床分析[J].中外医学研究,2011,9(16):36.
• [36] 王凤霞.复方甘草酸苷治疗慢性乙型肝炎60例疗效分析[J].中国医疗前沿,2011,6(18):26.
• [37] 邵寿祺.复方甘草酸苷治疗慢性乙型肝炎66例[C].宁波:2006年浙江省感染病、肝病学术会议,2006.
• [38] 陈军.复方甘草酸苷治疗慢性乙型肝炎66例疗效观察[J].华南国防医学杂志,2014,28(9):929.
• [39] 梁士兵,孙屿昕,李玉琦,等.小儿推拿治疗厌食症随机对照试验的方法学和干预措施报告质量评价[J].中华中医药学刊,2020,38(6):94.
• [40] MOHER D,SCHULZ K F,ALTMAN D.The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomized trials[J].JAMA,2001,285(15):1987.
• [41] 王丽琼,李青,苏春香,等.中医药随机对照试验中盲法的应用与评价[J].中医杂志,2014,55(1):28.
• [42] SCHULZ K F,ALTMAN D G,MOHER D.CONSORT 2010 statement:updated guidelines for reporting parallel group randomised trials[J].J Pharmacol Pharmacother,2010,1(2):100.